glp 1 agonist alcohol GLP-1 Therapeutics and Their Emerging Role in and Substance Use Disorders: An Endocrinology Primer A new clinical trial supported

The thoracic fluid index significantly decreased at Tmax of liraglutide, i.e

170 Diabetes may exacerbate the progression of PD, including cognitive impairment and axial motor symptoms

NIDA is sponsoring a randomized, placebo-controlled clinical trial evaluating Tirzepatide as treatment for cannabis use disorder

doi: 10.1038/ijo.2011.158 240 BlundellJFinlaysonGAxelsenMFlintAGibbonsCKvistTet al

28 The effect of weight loss through these recently approved, but increasingly used, drugs on nephrolithiasis risk in patients with known stone disease is not well understood

Nausea is one of the common gastrointestinal side effects of GLP-1 analogue use, especially with the short-acting analogues, but it tends to wane with time